Results of T2000 Clinical Studies in Essential Tremor Published in the Journal Movement Disorders.

Proprietary Taro Compounds Also Receive U.S. Patent for Essential Tremor and Parkinson's Disease 

HAWTHORNE, N.Y. -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets: TAROF) today announced that a paper titled, "Treatment of essential tremor with the barbiturate T2000" has been posted to the website of Movement Disorders, the journal of the Movement Disorders Society, prior to its appearance in the print version of that publication.

The paper discusses Phase II studies of T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), the first of Taro's proprietary, non-sedating barbiturate compounds to undergo clinical trials. The paper is available at www.movementdisordersjournal.org in the "Early View" section.

The paper reports the results of two brief, randomized, placebo-controlled, double-blind trials assessing the effectiveness of T2000 in treating essential tremor (involuntary shaking not related to Parkinson's disease). A total of 34 patients participated in the two trials. A statistically significant dose-dependent improvement was demonstrated, and four of the 23 patients treated with T2000 experienced marked improvement.

The clinical trials were conducted in Montreal. The principal author of the paper and the lead investigator of the studies is Calvin Melmed, M.D. of the Department of Neurology and Neurosurgery of McGill University, Montreal and Neurologist-in-Chief of SMBD-Jewish General Hospital, Montreal. Daniel Moros, M.D., and Howard Rutman, M.D., of Taro co-authored the paper.

As noted in the published report of the studies, T2000 shows, "Olittle sedation in animals and humans, which allows an exploration of the response to treatment at dosages not possible with other anticonvulsant or hypnotic barbiturates."

Estimates of the prevalence of essential tremor vary. For more information on essential tremor, visit www.essentialtremor.org, the website of the International Essential Tremor Foundation.

As previously announced, T2000 is currently being studied for the treatment of moderate to severe essential tremor in a multi-center, randomized, double-blind, placebo-controlled trial in Canada. Details of this Phase II study are available at the www.clinicaltrials.gov website maintained by the U.S. National Institutes of Health.

"The treatment of essential tremor remains challenging and frustrating for patients and physicians," said Barrie Levitt, M.D., Chairman of the Company. "This study demonstrates that additional trials are warranted to evaluate T2000 as a treatment option for this disorder."

U.S. Patents Issued

Taro also reported today that the U.S. Patent and Trademark Office has issued a patent to Taro for the use of the Company's proprietary, non-sedating barbiturate compounds in the treatment of essential tremor and Parkinson's disease. The patent will expire in June 2025.

There can be no assurance as to the outcome of any current or future study of these compounds, or that the FDA or any foreign equivalent will approve any product based on these compounds, or that any approved product will be commercially successful.

Taro is a multinational, science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For more information on Taro, please visit www.taro.com.

SAFE HARBOR STATEMENT

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's proprietary, non-sedating barbiturate compounds. Although Taro Pharmaceutical Industries Ltd. believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ include industry and market conditions; results of future studies; scientific developments in the field of essential tremor; approval by the FDA or its foreign equivalent of a product based on any of the Company's proprietary compounds; physician, pharmacist and consumer acceptance of such a product; changes in the Company's financial position; regulatory actions; and, other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update, change or revise any forward-looking statements, whether as a result of new information, additional or subsequent developments or otherwise.